Literature DB >> 8542566

Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

R H Hunt.   

Abstract

H2-receptor antagonists have been widely prescribed in the last 20 years and are considered to rank among the safest drugs known. In several countries they have been switched to over-the-counter (OTC) status, and a similar move is under consideration in Canada. Some concerns have been raised as to the effectiveness of these drugs in the treatment of dyspepsia and heartburn, their safety when taken for self-diagnosed symptoms, and the potential for their use to delay diagnosis or mask serious disease. The author presents evidence to support the use of OTC H2-receptor antagonists in the treatment of dyspepsia. He argues that the safety record of these drugs is reassuring and that they are unlikely to mask gastric cancer. Finally, he describes the appropriate place of OTC H2-receptor antagonists in the overall management of acid-related disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8542566      PMCID: PMC1488093     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  32 in total

1.  Pharmacy beyond the dispensary: general practitioners' views.

Authors:  J A Spencer; C Edwards
Journal:  BMJ       Date:  1992-06-27

Review 2.  Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases?

Authors:  S Holt
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

3.  Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine).

Authors:  Thomas J. Simon; Roger G. Berlin; Andrea H. Gardner; Laura A. Stauffer; A. Lawrence Gould; Albert J. Getson
Journal:  Am J Ther       Date:  1995-05       Impact factor: 2.688

4.  Is Helicobacter pylori the cause of dyspepsia?

Authors:  B Bernersen; R Johnsen; L Bostad; B Straume; A I Sommer; P G Burhol
Journal:  BMJ       Date:  1992-05-16

5.  Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin.

Authors:  R Gotthard; G Bodemar; U Brodin; K A Jönsson
Journal:  Scand J Gastroenterol       Date:  1988-01       Impact factor: 2.423

6.  Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors.

Authors:  L Kay; T Jørgensen
Journal:  Scand J Gastroenterol       Date:  1994-01       Impact factor: 2.423

7.  Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study.

Authors:  D G Colin-Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Br Med J (Clin Res Ed)       Date:  1982-11-06

8.  Prevalence of symptoms of dyspepsia in the community.

Authors:  R Jones; S Lydeard
Journal:  BMJ       Date:  1989-01-07

9.  Early gastric cancer: 46 cases treated in one surgical department.

Authors:  H M Sue-Ling; I Martin; J Griffith; D C Ward; P Quirke; M F Dixon; A T Axon; M J McMahon; D Johnston
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

Review 10.  When should endoscopy (or radiology) be used in dyspepsia and peptic ulcer disease?

Authors:  D G Colin-Jones
Journal:  Aliment Pharmacol Ther       Date:  1987       Impact factor: 8.171

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.